Vioxx heart risk starts earlier than previously reported; New England Journal of Medicine publishes corrections to previous Vioxx research

Email this article to a friend

Printable Version

Articles Related to This Article: • Merck litigation strategy - destroy expert witnesses • Leaked documents show Merck knew of Vioxx dangers, yet hid them for years • Merck caught in scandal to bury Vioxx heart attack risks, intimidate scientists and keep pushing dangerous drugs; Vioxx lawsuits now forming Sign the Health Revolution Petition Join the call for genuine health freedom in America. End FDA tyranny and Big Pharma corruption. Watch the video and sign the petition here.

(NaturalNews) -- Editors at the New England Journal of Medicine (NEJM) have published a correction to previous research on Merck's painkiller Vioxx. The correction reveals that the heart risks associated with the drug begin much earlier than Merck previously claimed.

The journal issued an online change to the "Approve" study, which indicated that heart problems began only after 18 months of use. Those results led researchers to believe the drug was safe for short-term use. However, after the study authors admitted to statistical errors in their analysis, NEJM published the correction, which stated that heart risks were elevated the entire time patients were on the drug.

Dr. Steven Nissen of the Cleveland Clinic, a vocal critic of Vioxx, wrote a letter in the latest NEJM issue, reminding readers that Merck had used the now-false claim that Vioxx was safe for 18 months of use as part of its defense in the 11,500 lawsuits brought against the company by patients claiming Vioxx-related health troubles.

Kamran Abbasi, editor of the Journal of the Royal Society of Medicine, and former editor of the British Medical Journal, says the corrections to the Approve study demonstrate how little medical journals can do to police the system of drug safety research. "The reality is that journals are at the whim of powerful companies and their research departments." Abbasi says.

Merck has issued a statement saying it "stands behind the original results" of the Approve study.

###

Get articles like this delivered to you FREE in our popular email newsletter

Related CounterThink Cartoons:

Related Articles: • Merck litigation strategy - destroy expert witnesses • Leaked documents show Merck knew of Vioxx dangers, yet hid them for years • Merck caught in scandal to bury Vioxx heart attack risks, intimidate scientists and keep pushing dangerous drugs; Vioxx lawsuits now forming	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/019478_Vioxx_medicine_Merck.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. Embed article link: (copy HTML code below): <a href = "http://www.NaturalNews.com/019478_Vioxx_medicine_Merck.html">Vioxx heart risk starts earlier than previously reported; New England Journal of Medicine publishes corrections to previous Vioxx research</a>